Anthrax vaccines: a development update.
The current human anthrax vaccines licensed in the US and UK consist of aluminum hydroxide-adsorbed or alum-precipitated culture supernatant material from fermentor cultures of toxigenic noncapsulated strains of Bacillus anthracis. The threat of B. anthracis being used as a biowarfare agent has led to a wider usage of these vaccines, which has heightened concerns regarding the need for frequent boosters and the occasional local reactogenicity associated with vaccination. These concerns have provided the impetus for the development of better characterized vaccines. This review summarizes the work of numerous laboratories in the search for alternative vaccines against anthrax that are well tolerated, provide long-lasting immunity, and are efficacious.
Little
Stephen F
SF
United States Army Medical Research Institute of Infectious Diseases, Frederick, Maryland, USA.
D000818:Animals; D000881:Anthrax / Q000276:immunology / Q000517:prevention & control*; D022122:Anthrax Vaccines / Q000276:immunology*; D000942:Antigens, Bacterial / Q000276:immunology; D001408:Bacillus anthracis / Q000276:immunology*; D002986:Clinical Trials as Topic; D016503:Drug Delivery Systems; D006801:Humans; D013171:Spores, Bacterial / Q000235:genetics / Q000276:immunology; D014613:Vaccines, Attenuated / Q000276:immunology; D019444:Vaccines, DNA / Q000276:immunology; D022462:Vaccines, Edible / Q000276:immunology; D014614:Vaccines, Synthetic / Q000276:immunology
D022122:Anthrax Vaccines; D000942:Antigens, Bacterial; D014613:Vaccines, Attenuated; D019444:Vaccines, DNA; D022462:Vaccines, Edible; D014614:Vaccines, Synthetic